AVTX - Avalo Therapeutics Inc

https://www.avalotx.com

Momentum: Bearish

Recent News

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.32

WAYNE, Pa., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following ...

Bullish

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 months, 3 weeks ago • score: 0.29

WAYNE, Pa., June 23, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: ...

Bullish

Avalo Therapeutics to Participate in Upcoming Investor Conferences - Avalo Therapeutics ( NASDAQ:AVTX )

Benzinga • 2 months, 3 weeks ago • score: 0.26

WAYNE, Pa., June 23, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:

Bullish

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )

Benzinga • 2 months, 4 weeks ago • score: 0.34

WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.

Bullish

Avalo Therapeutics to Participate in Upcoming Investor Conferences - Avalo Therapeutics ( NASDAQ:AVTX )

Benzinga • 3 months, 2 weeks ago • score: 0.25

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.

Bullish

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire • 3 months, 2 weeks ago • score: 0.28

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.

Neutral

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

GlobeNewswire • 4 months ago • score: 0.09

WAYNE, Pa., May 12, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025.

Bullish

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

GlobeNewswire • 4 months, 2 weeks ago • score: 0.25

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the ...

Bullish

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - Avalo Therapeutics ( NASDAQ:AVTX )

Benzinga • 4 months, 2 weeks ago • score: 0.23

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$16.00

52W Low

$3.39

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.89

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

1.77

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.19

EV/Revenue (<3 favorable)

90.67

P/S (TTM) (<3 favorable)

345.96

P/B (<3 favorable)

1.46

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

5.26%

Institutions (25–75% balanced)

64.11%

Shares Outstanding

13,152,400

Float

6,954,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

441,000

Gross Profit (TTM)

-28,163,000

EPS (TTM)

6.54

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-136.41%

ROE (TTM) (>15% strong)

-0.90%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.66

Momentum

Bearish momentum

Value

0.9555

1.0297

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025